These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22034009)

  • 41. Fibroblast growth factor receptor 4 as a potential prognostic and therapeutic marker in colorectal cancer.
    Li CS; Zhang SX; Liu HJ; Shi YL; Li LP; Guo XB; Zhang ZH
    Biomarkers; 2014 Feb; 19(1):81-5. PubMed ID: 24410190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy.
    Shim HJ; Shin MH; Kim HN; Kim JH; Hwang JE; Bae WK; Chung IJ; Cho SH
    Cancer Res Treat; 2016 Jan; 48(1):71-9. PubMed ID: 25989802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis.
    Matakidou A; El Galta R; Rudd MF; Webb EL; Bridle H; Eisen T; Houlston RS
    Br J Cancer; 2007 Jun; 96(12):1904-7. PubMed ID: 17519899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A single nucleotide change in the mouse genome accelerates breast cancer progression.
    Seitzer N; Mayr T; Streit S; Ullrich A
    Cancer Res; 2010 Jan; 70(2):802-12. PubMed ID: 20068154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Germline variant FGFR4  p.G388R exposes a membrane-proximal STAT3 binding site.
    Ulaganathan VK; Sperl B; Rapp UR; Ullrich A
    Nature; 2015 Dec; 528(7583):570-4. PubMed ID: 26675719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors.
    Ezzat S; Wang R; Pintilie M; Asa SL
    Oncotarget; 2017 Jan; 8(2):3481-3494. PubMed ID: 27966451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls.
    Xu B; Tong N; Chen SQ; Hua LX; Wang ZJ; Zhang ZD; Chen M
    BMC Cancer; 2011 Feb; 11():84. PubMed ID: 21349172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma.
    Morimoto Y; Ozaki T; Ouchida M; Umehara N; Ohata N; Yoshida A; Shimizu K; Inoue H
    Cancer; 2003 Nov; 98(10):2245-50. PubMed ID: 14601095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma.
    Streit S; Bange J; Fichtner A; Ihrler S; Issing W; Ullrich A
    Int J Cancer; 2004 Aug; 111(2):213-7. PubMed ID: 15197773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation.
    Roidl A; Berger HJ; Kumar S; Bange J; Knyazev P; Ullrich A
    Clin Cancer Res; 2009 Mar; 15(6):2058-66. PubMed ID: 19240166
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis.
    Heinzle C; Gsur A; Hunjadi M; Erdem Z; Gauglhofer C; Stättner S; Karner J; Klimpfinger M; Wrba F; Reti A; Hegedus B; Baierl A; Grasl-Kraupp B; Holzmann K; Grusch M; Berger W; Marian B
    Cancer Res; 2012 Nov; 72(22):5767-77. PubMed ID: 22971346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas.
    Wimmer E; Ihrler S; Gires O; Streit S; Issing W; Bergmann C
    World J Clin Oncol; 2019 Mar; 10(3):136-148. PubMed ID: 30949443
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.
    Hofstetter G; Concin N; Braicu I; Chekerov R; Sehouli J; Cadron I; Van Gorp T; Trillsch F; Mahner S; Ulmer H; Grimm C; Castillo-Tong DC; Zeillinger R; Zeimet AG; Vergote I
    Gynecol Oncol; 2013 Oct; 131(1):15-20. PubMed ID: 23877013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.
    Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
    Gynecol Oncol; 2010 Apr; 117(1):109-16. PubMed ID: 20056267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.
    Xu W; Li Y; Wang X; Chen B; Wang Y; Liu S; Xu J; Zhao W; Wu J
    Eur J Cancer; 2010 Dec; 46(18):3332-8. PubMed ID: 20638838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
    Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
    Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma.
    Yang Y; Zhou Y; Lu M; An Y; Li R; Chen Y; Lu DR; Jin L; Zhou WP; Qian J; Wang HY
    Mol Carcinog; 2012 Jul; 51(7):515-21. PubMed ID: 21656577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
    Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.